Integrated Quantitative Investments LLC Acquires New Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Integrated Quantitative Investments LLC purchased a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 77,266 shares of the biotechnology company's stock, valued at approximately $1,325,000.

A number of other hedge funds have also bought and sold shares of the business. Cerity Partners LLC increased its holdings in ADMA Biologics by 151.4% during the third quarter. Cerity Partners LLC now owns 50,878 shares of the biotechnology company's stock worth $1,017,000 after buying an additional 30,637 shares during the last quarter. FMR LLC increased its stake in shares of ADMA Biologics by 3.7% during the 3rd quarter. FMR LLC now owns 1,944,831 shares of the biotechnology company's stock worth $38,877,000 after purchasing an additional 68,881 shares during the last quarter. Walleye Capital LLC raised its holdings in shares of ADMA Biologics by 52.9% in the 3rd quarter. Walleye Capital LLC now owns 73,568 shares of the biotechnology company's stock worth $1,471,000 after purchasing an additional 25,442 shares during the period. Verition Fund Management LLC lifted its stake in ADMA Biologics by 1,198.1% in the third quarter. Verition Fund Management LLC now owns 145,985 shares of the biotechnology company's stock valued at $2,918,000 after purchasing an additional 134,739 shares during the last quarter. Finally, HighTower Advisors LLC grew its holdings in ADMA Biologics by 41.1% during the third quarter. HighTower Advisors LLC now owns 87,471 shares of the biotechnology company's stock valued at $1,748,000 after purchasing an additional 25,492 shares during the period. 75.68% of the stock is currently owned by institutional investors.

Remove Ads

ADMA Biologics Stock Performance

ADMA Biologics stock traded down $0.10 during mid-day trading on Wednesday, reaching $17.76. The company's stock had a trading volume of 636,865 shares, compared to its average volume of 2,758,209. The firm's fifty day moving average price is $17.55 and its two-hundred day moving average price is $18.16. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a 12-month low of $5.89 and a 12-month high of $23.64. The company has a market capitalization of $4.20 billion, a P/E ratio of 63.70 and a beta of 0.53.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.